Newron Seeks New Assets To Grow Pipeline
Newron has raised $27m via a private placement to fund late-stage development of its novel schizophrenia drug and to license new assets that will bulk up its limited clinical pipeline.
You may also be interested in...
Safinamide appears to be headed for a debut on the Indian market, after Sun Pharma received a go-ahead from a key expert panel for the Parkinson’s disease treatment. Pricing of the selective monoamine oxidase B inhibitor and innovator Newron’s stance around the emerging India activity for the product could be interesting to watch.
Newron Pharmaceuticals will file its investigational drug sarizotan in 2018 for respiratory issues in patients with Rett syndrome, setting it up to be the first therapy specifically indicated for this rare genetic disease. CEO Stefan Weber spoke to Scrip about Newron's commercial strategy for sarizotan and broader prospects for the evolving drug developer.
Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.